The South Korea blastic plasmacytoid dendritic cell neoplasm (BPDCN) market, valued at USD 42.88 million in 2024, is forecast to expand at a compound annual growth rate (CAGR) of 7.20% between 2025 and 2034, reaching an estimated USD 85.78 million by 2034. Growth will be propelled by improved disease awareness, advancements in targeted therapies, wider diagnostic...